KURA - Kura Oncology Inc Stock Price, Fair Value and News

$20.26+0.10 (+0.50%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

KURA RSI Chart

KURA Valuation

Market Cap

1.5B

Price/Earnings (Trailing)

-8.5

Price/Sales (Trailing)

99.53

Price/Free Cashflow

-9.98

KURA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

KURA Fundamentals

KURA Revenue

Revenue (TTM)

14.7M

Rev. Growth (Yr)

86.12%

Rev. Growth (Qtr)

24.69%

KURA Earnings

Earnings (TTM)

-181.8M

Earnings Growth (Yr)

-36.75%

Earnings Growth (Qtr)

-2.65%

KURA Price Action

Last 7 days

2.2%

Last 30 days

4.8%

Last 90 days

2.0%

Trailing 12 Months

110.3%

KURA Profitability

Return on Equity

-39%

Return on Assets

-35.28%

Free Cashflow Yield

-10.02%

KURA Financial Health

Current Ratio

14.94

Debt/Equity

0.02

Debt/Cashflow

-18.04

KURA Investor Care

Shares Dilution (1Y)

3.23%

Diluted EPS (TTM)

-2.23

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	6.8M	9.4M	0	14.7M
2022	1.2M	1.5M	2.3M	4.3M
2021	2.0M	0	1.5M	1.2M
2020	5.0M	4.8M	4.0M	2.8M
2019	3.7M	4.1M	4.5M	4.9M
2018	1.0M	1.5M	2.4M	3.2M
2017	780.0K	709.0K	711.0K	784.5K
2016	1.2M	1.1M	990.0K	885.0K
2015	0	0	1.2M	1.2M
2014	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

CEO	Dr. Troy Edward Wilson J.D., Ph.D.
WEBSITE	https://kuraoncology.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	133

Kura Oncology Inc Frequently Asked Questions

What is the ticker symbol for Kura Oncology Inc? What does KURA stand for in stocks?

KURA is the stock ticker symbol of Kura Oncology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Kura Oncology Inc (KURA)?

As of Tue Sep 17 2024, market cap of Kura Oncology Inc is 1.54 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KURA stock?

You can check KURA's fair value in chart for subscribers.

Is Kura Oncology Inc a good stock to buy?

The fair value guage provides a quick view whether KURA is over valued or under valued. Whether Kura Oncology Inc is cheap or expensive depends on the assumptions which impact Kura Oncology Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KURA.

What is Kura Oncology Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Sep 17 2024, KURA's PE ratio (Price to Earnings) is -8.5 and Price to Sales (PS) ratio is 99.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KURA PE ratio will change depending on the future growth rate expectations of investors.